We serve Chemical Name:2-(2-bromophenyl)-4,5-dihydrooxazole CAS:51816-27-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(2-bromophenyl)-4,5-dihydrooxazole
CAS.NO:51816-27-4
Synonyms:2-(2-bromophenyl)-4,5-dihydrooxazole
Molecular Formula:C9H8BrNO
Molecular Weight:226.07000
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:21.59000
Exact Mass:224.97900
LogP:1.66150
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(2-bromophenyl)-4,5-dihydrooxazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(2-bromophenyl)-4,5-dihydrooxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(2-bromophenyl)-4,5-dihydrooxazole Use and application,2-(2-bromophenyl)-4,5-dihydrooxazole technical grade,usp/ep/jp grade.
Related News: Slow business: Due to fear — and travel warnings — fewer people want to travel to China. 2-(2-bromophenyl)-4,5-dihydrooxazole manufacturer In order to seize the highest point of profits, international industry giants have adjusted their development strategies, concentrated their energies on the two ends of the smile curve-research and development and end products, and shifted production links such as intermediates and APIs outward. A division of labor model has been formed. 2-(2-bromophenyl)-4,5-dihydrooxazole supplier Slow business: Due to fear — and travel warnings — fewer people want to travel to China. 2-(2-bromophenyl)-4,5-dihydrooxazole vendor Pharmaceutical intermediates and APIs belong to the fine chemical industry. 2-(2-bromophenyl)-4,5-dihydrooxazole factory For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.”